Galectin Therapeutics Inc. (NASDAQ: GALT) announced the publication of results from its NAVIGATE Phase 2b clinical trial in the Journal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE